Ovarian Low-grade and High-grade Serous Carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Silverberg, 2000, Histopathologic grading of ovarian carcinoma: a review and proposal, Int J Gynecol Pathol, 19, 7, 10.1097/00004347-200001000-00003
Shimizu, 1998, Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up, Cancer, 82, 893, 10.1002/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W
Ayhan, 2009, Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis, Am J Surg Pathol, 33, 1220, 10.1097/PAS.0b013e3181a24354
Burks, 1996, Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors, Am J Surg Pathol, 20, 1319, 10.1097/00000478-199611000-00003
Dehari, 2007, The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis, Am J Surg Pathol, 31, 1007, 10.1097/PAS.0b013e31802cbbe9
Gershenson, 2006, Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary, Obstet Gynecol, 108, 361, 10.1097/01.AOG.0000227787.24587.d1
Hsu, 2004, Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas, Clin Cancer Res, 10, 6432, 10.1158/1078-0432.CCR-04-0893
Hsu, 2005, Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome, Hum Pathol, 36, 1049, 10.1016/j.humpath.2005.07.014
Kuo, 2009, Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas, Cancer Res, 69, 4036, 10.1158/0008-5472.CAN-08-3913
Malpica, 2004, Grading ovarian serous carcinoma using a two-tier system, Am J Surg Pathol, 28, 496, 10.1097/00000478-200404000-00009
Malpica, 2007, Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma, Am J Surg Pathol, 31, 1168, 10.1097/PAS.0b013e31803199b0
Pohl, 2005, Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations, Cancer Res, 65, 1994, 10.1158/0008-5472.CAN-04-3625
Salani, 2008, Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance, Int J Gynecol Cancer, 18, 487, 10.1111/j.1525-1438.2007.01039.x
Santillan, 2007, Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma, Int J Gynecol Cancer, 17, 601, 10.1111/j.1525-1438.2007.00820.x
Schmeler, 2008, Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum, Gynecol Oncol, 108, 510, 10.1016/j.ygyno.2007.11.013
Shih, 2004, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol, 164, 1511, 10.1016/S0002-9440(10)63708-X
Shih, 2005, Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma, Proc Natl Acad Sci USA, 102, 14004, 10.1073/pnas.0504195102
Shvartsman, 2007, Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma, Gynecol Oncol, 105, 625, 10.1016/j.ygyno.2007.01.030
Singer, 2002, Diverse tumorigenic pathways in ovarian serous carcinoma, Am J Pathol, 160, 1223, 10.1016/S0002-9440(10)62549-7
Singer, 2003, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma, J Natl Cancer Inst, 95, 484, 10.1093/jnci/95.6.484
Singer, 2003, Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor), Int J Gynecol Pathol, 22, 37, 10.1097/00004347-200301000-00009
Singer, 2005, Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation, Am J Surg Pathol, 29, 218, 10.1097/01.pas.0000146025.91953.8d
Smith Sehdev, 2003, Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases, Am J Surg Pathol, 27, 725, 10.1097/00000478-200306000-00003
Vang, 2008, Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data, Am J Surg Pathol, 32, 1667, 10.1097/PAS.0b013e31816fd555
McKenney, 2006, Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion, Am J Surg Pathol, 30, 1209, 10.1097/01.pas.0000213299.11649.fa
Seidman, 2004, Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images, Hum Pathol, 35, 918, 10.1016/j.humpath.2004.03.004
Bell, 2004, Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives, Hum Pathol, 35, 934, 10.1016/j.humpath.2004.03.005
Longacre, 2005, Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up, Am J Surg Pathol, 29, 707, 10.1097/01.pas.0000164030.82810.db
Alvarez, 2001, K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary, Gynecol Oncol, 80, 201, 10.1006/gyno.2000.6066
Haas, 1999, In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential, Virchows Arch, 434, 117, 10.1007/s004280050314
Mayr, 2006, KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants, Gynecol Oncol, 103, 883, 10.1016/j.ygyno.2006.05.029
Sieben, 2004, In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours, J Pathol, 202, 336, 10.1002/path.1521
Ho, 2004, Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors, Cancer Res, 64, 6915, 10.1158/0008-5472.CAN-04-2067
Staebler, 2002, Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas, Hum Pathol, 33, 47, 10.1053/hupa.2002.30212
Bonome, 2005, Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary, Cancer Res, 65, 10602, 10.1158/0008-5472.CAN-05-2240
Nakayama, 2006, Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms, Cancer Biol Ther, 5, 779, 10.4161/cbt.5.7.2751
Nakayama, 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer, Br J Cancer, 99, 2020, 10.1038/sj.bjc.6604783
Davidson, 2006, Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma, Clin Cancer Res, 12, 5944, 10.1158/1078-0432.CCR-06-1059
Santin, 2004, Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy, Int J Cancer, 112, 14, 10.1002/ijc.20408
Pothuri, 2001, Genetic analysis of ovarian carcinoma histogenesis (Abstract), Gynecol Oncol, 80, 277
Werness, 2000, Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53, J Natl Cancer Inst, 92, 1088, 10.1093/jnci/92.13.1088
Pal, 2005, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 104, 2807, 10.1002/cncr.21536
Risch, 2001, Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer, Am J Hum Genet, 68, 700, 10.1086/318787
Geisler, 2002, Frequency of BRCA1 dysfunction in ovarian cancer, J Natl Cancer Inst, 94, 61, 10.1093/jnci/94.1.61
Hilton, 2002, Inactivation of BRCA1 and BRCA2 in ovarian cancer, J Natl Cancer Inst, 94, 1396, 10.1093/jnci/94.18.1396
Bell, 2005, Origins and molecular pathology of ovarian cancer, Mod Pathol, 18, S19, 10.1038/modpathol.3800306
Bell, 1994, Early de novo ovarian carcinoma. A study of fourteen cases, Cancer, 73, 1859, 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L
Carlson, 2008, Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention, J Clin Oncol, 26, 4160, 10.1200/JCO.2008.16.4814
Jarboe, 2008, Serous carcinogenesis in the fallopian tube: a descriptive classification, Int J Gynecol Pathol, 27, 1, 10.1097/pgp.0b013e31814b191f
Jarboe, 2008, Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective, Histopathology, 53, 127, 10.1111/j.1365-2559.2007.02938.x
Kindelberger, 2007, Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship, Am J Surg Pathol, 31, 161, 10.1097/01.pas.0000213335.40358.47
Medeiros, 2006, The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J Surg Pathol, 30, 230, 10.1097/01.pas.0000180854.28831.77
Lee, 2007, A candidate precursor to serous carcinoma that originates in the distal fallopian tube, J Pathol, 211, 26, 10.1002/path.2091
Silva, 1997, Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma, Mod Pathol, 10, 663
Parker, 2004, Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases, Int J Gynecol Pathol, 23, 265, 10.1097/01.pgp.0000130049.19643.f6
Seidman, 2006, Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum, Gynecol Oncol, 103, 703, 10.1016/j.ygyno.2006.05.030
Gilks, 2008, Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma, Hum Pathol, 39, 1239, 10.1016/j.humpath.2008.01.003
Yemelyanova, 2008, Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion, Am J Surg Pathol, 32, 1800, 10.1097/PAS.0b013e318181a7ce
Che, 2001, Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells, Int J Gynecol Pathol, 20, 323, 10.1097/00004347-200110000-00002
Ishioka, 2003, Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system, Gynecol Oncol, 89, 447, 10.1016/S0090-8258(03)00133-1
Bloss, 1993, Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary, Gynecol Oncol, 50, 347, 10.1006/gyno.1993.1223
Hu, 1950, Primary carcinoma of the fallopian tube, Am J Obstet Gynecol, 59, 58, 10.1016/0002-9378(50)90341-3
Sedlis, 1978, Carcinoma of the fallopian tube, Surg Clin North Am, 58, 121, 10.1016/S0039-6109(16)41439-8
Ayhan, 2006, Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?, Int J Gynecol Cancer, 16, 484, 10.1111/j.1525-1438.2006.00590.x
Baekelandt, 2000, Carcinoma of the fallopian tube, Cancer, 89, 2076, 10.1002/1097-0142(20001115)89:10<2076::AID-CNCR7>3.0.CO;2-V
Barda, 2004, Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study, Am J Obstet Gynecol, 190, 1039, 10.1016/j.ajog.2003.09.073
Ben-Baruch, 1996, Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma, Gynecol Oncol, 60, 393, 10.1006/gyno.1996.0060
Bloss, 2003, Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study, Gynecol Oncol, 89, 148, 10.1016/S0090-8258(03)00068-4
Dubernard, 2004, Prognosis of stage III or IV primary peritoneal serous papillary carcinoma, Eur J Surg Oncol, 30, 976, 10.1016/j.ejso.2004.08.005
Eltabbakh, 2000, Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma, J Surg Oncol, 73, 148, 10.1002/(SICI)1096-9098(200003)73:3<148::AID-JSO7>3.0.CO;2-U
Jaaback, 2006, Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period, Int J Gynecol Cancer, 16, 123, 10.1136/ijgc-00009577-200602001-00020
Khalifeh, 2004, Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma, Int J Gynecol Pathol, 23, 162, 10.1097/00004347-200404000-00011
Moore, 2007, Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary, Gynecol Oncol, 107, 398, 10.1016/j.ygyno.2007.09.027
O'Neill, 2005, An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms, Am J Surg Pathol, 29, 1034, 10.1097/01.pas.0000166367.68459.7d
Reid-Nicholson, 2006, Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis, Mod Pathol, 19, 1091, 10.1038/modpathol.3800620
Armes, 2005, Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein, Int J Gynecol Pathol, 24, 363, 10.1097/01.pgp.0000172083.94934.1e
O'Neill, 2007, High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour, Histopathology, 50, 773, 10.1111/j.1365-2559.2007.02682.x
Vang, 2007, p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas, Am J Surg Pathol, 31, 653, 10.1097/01.pas.0000213369.71676.25
Bhargava, 2007, Mammaglobin vs. GCDFP-15: an immunohistologic validation survey for sensitivity and specificity, Am J Clin Pathol, 127, 103, 10.1309/TDP92PQLDE2HLEET
Nonaka, 2008, Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas, Am J Surg Pathol, 32, 1566, 10.1097/PAS.0b013e31816d71ad
Tornos, 2005, Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary, Am J Surg Pathol, 29, 1482, 10.1097/01.pas.0000176429.88702.36
Nakayama, 2006, A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival, Proc Natl Acad Sci USA, 103, 18739, 10.1073/pnas.0604083103